List of Excipients in Branded Drug ELIMITE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prestium Pharma Inc	ELIMITE	permethrin	40076-230	BUTYLATED HYDROXYTOLUENE
Prestium Pharma Inc	ELIMITE	permethrin	40076-230	CARBOMER HOMOPOLYMER TYPE B
Prestium Pharma Inc	ELIMITE	permethrin	40076-230	FORMALDEHYDE
Prestium Pharma Inc	ELIMITE	permethrin	40076-230	GLYCERIN

ELIMITE Excipient Strategy and Commercial Opportunities for Permethrin 5% Cream

Last updated: September 1, 2026

ELIMITE is a topical permethrin 5% cream for scabies treatment. Its commercial value is no longer driven by compound exclusivity. The opportunity lies in improving vehicle performance, tolerability, packaging, patient adherence, and channel economics while maintaining pharmaceutical equivalence to established generic products.

The base formulation is a conventional oil-in-water cream containing permethrin with fatty alcohols, isopropyl myristate, glycerin, sorbitan monooleate, polysorbate 60, and purified water. A new entrant should treat the product as a formulation and execution opportunity rather than a patent-protected branded asset. FDA approval risk will center on active-ingredient uniformity, particle size, rheology, preservative control, microbiological quality, dermal tolerability, and comparative performance against the reference product.[1][2]

What is ELIMITE and what excipients does it contain?

ELIMITE Cream 5% contains permethrin, a synthetic pyrethroid insecticide used for topical treatment of scabies. The product is applied to the skin and typically remains in contact with the skin for an extended period before removal, making spreadability, skin feel, residue, and irritation important commercial attributes.

Public labeling identifies the following inactive ingredients:

Excipient	Likely formulation function
Cetyl alcohol	Consistency agent, emollient, co-emulsifier
Stearyl alcohol	Viscosity builder, emollient, co-emulsifier
Isopropyl myristate	Emollient, spreading aid, penetration and sensory modifier
Glycerin	Humectant
Sorbitan monooleate	Lipophilic emulsifier
Polysorbate 60	Hydrophilic emulsifier
Purified water	Continuous aqueous phase

The formulation uses a standard nonionic emulsifier system. That approach supports manufacturing robustness and generally avoids the ionic incompatibility risks associated with anionic or cationic surfactants. The fatty alcohol blend provides body and helps create a cream that can remain on the skin during the treatment interval.[1]

What excipient strategy is most suitable for a new permethrin cream?

The strongest strategy is a controlled reformulation that improves patient experience without materially changing the product's clinical performance.

1. Preserve the basic oil-in-water architecture

A conventional oil-in-water cream is commercially defensible because it is familiar to patients, physicians, pharmacists, and generic manufacturers. It can accommodate the lipophilic permethrin molecule while permitting aqueous-phase humectants and conventional tube filling.

The core excipient strategy should preserve:

• A nonionic emulsifier system
• A fatty alcohol structural network
• A moderate emollient load
• Adequate water activity control
• A neutral-to-mildly acidic skin-compatible pH
• Low odor and low residue

A major departure from the reference vehicle would increase comparative formulation and clinical development risk. A Q1/Q2-matched generic product would generally have a clearer ANDA path than a materially different delivery system.[2][3]

2. Improve spreadability and washability

Isopropyl myristate improves glide and can reduce the heavy feel associated with fatty alcohol creams. Its level should be balanced against potential irritation, excessive skin penetration, and greasy residue.

Potential alternatives or partial replacements include:

• Caprylic/capric triglyceride
• C12-15 alkyl benzoate
• Diisopropyl adipate
• Hydrogenated polyisobutene
• Light silicone emollients, subject to regulatory and compatibility review

The commercial target is a cream that spreads rapidly over large skin areas, including the trunk and limbs, without dripping or requiring repeated rubbing. Washability also matters because patients remove the product after the prescribed contact period.

3. Reduce irritation and allergy concerns

Excipient selection should avoid unnecessary fragrance, essential oils, colorants, and high-irritancy preservatives. Scabies patients may already have excoriated or inflamed skin, and pediatric use increases sensitivity to avoidable formulation irritants.

A differentiated product could use:

• Fragrance-free composition
• Dye-free composition
• Low-allergen preservative system
• Lower residual surfactant load
• Reduced formaldehyde-releasing preservative risk
• Packaging that minimizes contamination during repeated handling

Any preservative change requires preservative-effectiveness testing, microbial limits testing, stability testing, and compatibility evaluation with the tube or pump system.[4][5]

4. Control particle size and dispersion

Permethrin is a hydrophobic active ingredient. The formulation must control its dispersion or dissolution state to avoid dose nonuniformity and changes in topical delivery.

Critical development parameters include:

• Permethrin particle-size distribution
• Wetting and deagglomeration
• Homogenization energy
• Addition sequence
• Cooling profile
• Viscosity at filling temperature
• Long-term physical stability
• Assay uniformity across the batch

A formulation with a smaller or more controlled particle-size distribution may improve consistency, but it could also alter dermal delivery. Such a change should be evaluated against the reference product rather than assumed to be clinically neutral.

What commercial formulation opportunities exist for ELIMITE alternatives?

The largest opportunities are product differentiation and channel expansion rather than premium pricing based solely on the permethrin molecule.

Sensitive-skin permethrin cream

A fragrance-free, dye-free, low-irritancy product could target pediatric patients, patients with eczema-prone skin, and households treating multiple family members. The product should avoid claiming superior clinical efficacy unless supported by appropriate data.

The commercial message can focus on formulation attributes such as:

• No added fragrance
• No dyes
• Easily spreadable cream
• Low-residue vehicle
• Dermatologist-tested tolerability, if substantiated

Pediatric-oriented packaging

Scabies treatment frequently involves children and household contacts. Packaging can improve dosing execution without changing the formulation.

Potential formats include:

• Unit-dose or multi-unit tubes
• Metered-dose pumps
• Child-resistant secondary packaging
• Instructional carton panels
• Treatment checklists
• Household treatment kits

A pump may improve hygiene and reduce cap contamination, but it introduces risks involving dose accuracy, priming, residual product, and compatibility with the emulsion.

High-volume institutional packaging

Long-term-care facilities, correctional facilities, shelters, and public-health programs may value larger tubes, case packs, and simplified administration instructions. This segment is price sensitive and tends to prioritize supply reliability, shelf life, and packaging efficiency.

A commercial supplier could offer:

• Standard retail tubes
• Institutional bulk packaging
• Contract-manufactured private-label products
• Government procurement packs
• Pharmacy dispensing formats

Packaging changes must preserve the approved container-closure system or undergo the required regulatory evaluation.

Combination and household-treatment offerings

Permethrin cream treats scabies, but the broader commercial problem involves household transmission and environmental control. A company could develop a permitted product family that includes:

• Permethrin 5% cream
• Separate laundering or environmental-care products
• Patient instruction materials
• Household treatment scheduling tools
• Clinical or pharmacy support services

A separate environmental product must comply with the applicable pesticide, consumer-product, or other regulatory framework. It should not be presented as part of the drug's approved indication unless authorized.

What FDA regulatory pathway applies to a new ELIMITE product?

A conventional generic permethrin 5% cream would generally be pursued through an abbreviated new drug application, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA's product-specific requirements.[2][3]

Key regulatory issues include:

Development issue	Commercial relevance
Same active ingredient and strength	Supports generic product classification
Same dosage form and route	Reduces regulatory divergence
Q1/Q2 formulation alignment	May reduce comparative risk
In vitro release and performance testing	Supports product comparison
Dermal tolerability	Important for inflamed and pediatric skin
Container-closure compatibility	Affects shelf life and dose delivery
Microbiological quality	Critical for an aqueous topical cream
Stability under controlled and accelerated conditions	Determines commercial shelf life

A materially novel vehicle could fall outside a straightforward ANDA strategy. Depending on the formulation and claims, development might require a 505(b)(2) application or a new drug application. That route could support a differentiated label or delivery system, but it would carry higher development cost and a longer regulatory timeline.[3]

What is the Orange Book and patent status of ELIMITE?

ELIMITE is not an attractive target for a patent-extension strategy based on the original permethrin composition. Permethrin 5% cream has been commercially available for decades, and generic competition has substantially reduced the value of basic composition protection.

The relevant protection landscape is:

Protection category	Strategic assessment
Original permethrin composition patents	Expired or commercially irrelevant
Basic 5% cream formulation	Weak protection in view of long generic history
Method-of-use protection for scabies	Limited practical exclusivity value
New excipient combination	Potentially patentable if technically unexpected
Novel packaging or delivery system	Potentially protectable, but narrower
Manufacturing process	May provide trade-secret value
Brand and trade dress	Possible commercial protection, not product exclusivity

FDA's Orange Book identifies approved drug products and applicable listed patents for eligible prescription products. A new applicant should confirm the current listing status directly in the FDA Orange Book before making launch or litigation decisions.[6]

The strongest intellectual-property strategy would focus on a narrowly defined improvement, such as:

• A stable low-irritancy vehicle
• A specific particle-size distribution
• A pump-delivered formulation with dose uniformity
• A low-residue cream with demonstrated performance advantages
• A manufacturing process that reduces aggregation or improves homogeneity

Patentability would depend on novelty, non-obviousness, enablement, and credible technical results. A generic cream that merely substitutes one conventional emollient for another would face a weak patent position.

When does ELIMITE lose exclusivity, and what generic-entry risks exist?

The practical exclusivity period has already ended for the original product concept. Current competition is primarily generic and often price based.

Generic-entry risks include:

1. Price erosion from multiple permethrin 5% cream suppliers.
2. Pharmacy substitution where state law and payer policy permit.
3. Private-label erosion in retail and institutional channels.
4. Supply disruptions caused by limited contract manufacturing capacity.
5. Product complaints involving odor, residue, separation, or difficult application.
6. Regulatory scrutiny if a reformulated product changes topical performance.

A differentiated entrant can reduce direct price comparison by targeting a specific unmet commercial need, but the product must retain the low-cost economics expected for an established topical generic.

Are Paragraph IV challenges relevant to ELIMITE?

Paragraph IV litigation is relevant only if a marketed reference product has unexpired Orange Book-listed patents. For an established permethrin cream, the main commercial issue is unlikely to be an active patent challenge against the original formulation. The more relevant scenarios are:

• A branded reformulation with newly listed patents
• A novel delivery system supported by a later patent estate
• A 505(b)(2) product asserting formulation or method-of-use protection
• A generic applicant challenging patents covering a new premium product

If a company launches a new branded permethrin formulation, it should expect potential Paragraph IV exposure once an ANDA applicant identifies listed patents. Any patent estate should therefore contain claims directed to measurable formulation attributes, not only broad claims to topical permethrin treatment.

Which companies are challenging or competing with ELIMITE?

Competition comes from generic pharmaceutical manufacturers rather than biosimilar developers. Permethrin is a small-molecule active ingredient, so biosimilar risk does not apply.

Competitive categories include:

Competitor type	Competitive basis
Generic permethrin 5% creams	Lowest acquisition cost and formulary access
Branded scabies treatments	Brand recognition and distribution
Alternative topical scabicides	Different active ingredients or dosing schedules
Oral ivermectin	Different route and treatment model, subject to indication and clinical considerations
Institutional suppliers	Contract pricing and supply reliability
Compounded products	Limited, channel-specific alternative with different regulatory status

The primary competitive advantage for a new product would be reliable supply, favorable pharmacy economics, better patient handling, or a clearly differentiated vehicle.

What manufacturing and intellectual-property barriers affect commercial launch?

Manufacturing execution is a larger barrier than basic excipient availability. Common risks include:

• Nonuniform permethrin distribution
• Emulsion inversion or phase separation
• Crystal growth during storage
• Inconsistent viscosity
• Tube-fill variability
• Active adsorption into packaging
• Preservative loss
• Microbial contamination
• Batch-to-batch sensory variation

Process controls should cover raw-material specifications, premix temperature, homogenization, cooling rate, bulk hold time, deaeration, and filling conditions.

Trade-secret protection may be more useful than patents for process parameters that are difficult to reverse engineer. The company should also secure supply agreements for pharmaceutical-grade excipients and qualify at least one backup source for critical materials.

How strong is the patent estate for an improved permethrin cream?

The patent estate for the legacy product is weak. A new formulation could create a moderate patent position if it demonstrates a specific technical benefit that is not predictable from standard formulation practice.

Patent strength would be highest where claims cover:

• Defined excipient ratios
• A narrow particle-size range
• A measurable rheological profile
• Improved stability under stress conditions
• Reduced irritation supported by comparative testing
• Dose delivery from a specified container system
• A manufacturing sequence linked to product performance

Patent strength would be lower for generic claims covering "a topical composition comprising permethrin and an emollient" or routine substitutions among well-known cream excipients.

What revenue exposure and launch scenarios should investors assess?

Revenue exposure depends on whether the product is positioned as a commodity generic or differentiated branded formulation.

Launch model	Margin profile	Main risk
ANDA generic cream	Low to moderate	Rapid price competition
Private-label institutional product	Low	Contract concentration
Branded sensitive-skin cream	Moderate	Limited willingness to pay
Pump or unit-dose product	Moderate to high	Device and packaging costs
505(b)(2) differentiated product	Potentially high	Development and regulatory expense
International licensing product	Variable	Local registration and pricing controls

A practical launch strategy is to begin with a Q1/Q2-aligned cream for regulatory and supply access, then develop a differentiated packaging or vehicle variant after establishing manufacturing capability. Licensing opportunities are more likely to involve regional distribution, private-label supply, or contract manufacturing than valuable compound rights.

Key Takeaways

• ELIMITE is a permethrin 5% topical cream with a conventional oil-in-water excipient system.
• Original compound and basic formulation exclusivity do not provide a meaningful commercial barrier.
• The strongest opportunities are fragrance-free, low-irritancy, low-residue, pediatric-oriented, and institutionally efficient products.
• A Q1/Q2-aligned formulation supports the clearest generic regulatory strategy.
• Novel excipient combinations require comparative performance and tolerability evidence to justify premium positioning.
• Biosimilar risk is not relevant because permethrin is a small molecule.
• Paragraph IV exposure becomes relevant mainly for newly developed branded formulations with listed patents.
• Manufacturing consistency, packaging performance, and supply reliability are more important barriers than legacy patent protection.
• Commercial returns will depend on channel selection, product differentiation, and resistance to generic price erosion.

FAQs

Can a new company sell permethrin 5% cream without using the ELIMITE brand?

Yes. A company can pursue an approved generic product using its own proprietary name or an unbranded label, subject to FDA approval and applicable trademark restrictions.

Is a fragrance-free permethrin cream automatically patentable?

No. Fragrance removal alone is generally unlikely to support a strong patent unless it is part of a novel formulation that produces an unexpected technical result.

Can a permethrin cream be converted from a tube to a pump?

Potentially, but the sponsor must demonstrate dose delivery, container compatibility, stability, microbial protection, and appropriate performance for the proposed packaging system.

Does a different excipient create a new drug product?

Not necessarily. A formulation with different inactive ingredients may still qualify as a generic if it satisfies applicable FDA requirements. A material change in formulation, performance, labeling, or claims can require a different regulatory pathway.

Is oral ivermectin a direct substitute for ELIMITE?

It is a different treatment option with a different route, dosing model, regulatory status, and clinical profile. It should be assessed as a competitive alternative rather than as a formulation substitute.

References

1. DailyMed. (n.d.). ELIMITE- permethrin cream. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic and semi-synthetic drug substances: Product-specific guidance. FDA.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2016). Microbiological quality considerations in non-sterile drug manufacturing. FDA.
5. United States Pharmacopeial Convention. (2023). General chapter <51>: Antimicrobial effectiveness testing. USP-NF.
6. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.